{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:09:22Z","timestamp":1784124562831,"version":"3.55.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate, in a large real-world cohort of people living with HIV (PLWH) treated with bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) or dolutegravir\/lamivudine, rates of virological failure (VF) and resistance emergence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All PLWH receiving BIC\/FTC\/TAF or dolutegravir\/lamivudine without prior NRTI or integrase strand transfer inhibitor (InSTI) resistance-associated mutations (RAMs) and with at least 6 month follow-up between January 2018 and January 2025 were included in this retrospective single-centre study. Demographic, therapeutic and immunovirological data were collected from electronic medical records. VF was defined as confirmed HIV RNA &amp;gt;50\u2005copies\/mL or a single HIV RNA &amp;gt;200\u2005copies\/mL followed by modification of treatment. Blip was defined as a single HIV RNA between 50 and 200\u2005copies\/mL. These thresholds were applied after &amp;gt;6\u2005months of first-line therapy (FLT), or at any timepoint in virological suppression maintenance therapy (MT). Plasma HIV genotyping by Sanger sequencing was performed at the clinician\u2019s request, and resistance was interpreted using the ANRS algorithm V35.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1059 PLWH were included: 594 receiving BIC\/FTC\/TAF (141 FLT and 453 MT) and 465 receiving dolutegravir\/lamivudine (23 FLT and 442 MT). VF occurred in 79\/1059 PLWH (7.5% overall; 9.8% in the BIC\/FTC\/TAF group and 4.5% in the dolutegravir\/lamivudine group) and blips in 96\/1059 PLWH (9.0% overall; 9.9% and 5.8%, respectively, groupwise). Resistance emergence was documented in nine cases (0.9%), four for BIC\/FTC\/TAF (InSTI-RAM in 1\/4) and five for dolutegravir\/lamivudine (InSTI-RAM in 3\/5).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this real-world cohort, InSTI resistance emergence in PLWH failing BIC\/FTC\/TAF or dolutegravir\/lamivudine was rare at 0.17% and 0.65%, respectively, supporting the robustness of these InSTI-based regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag247","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:22:33Z","timestamp":1783336953000},"source":"Crossref","is-referenced-by-count":0,"title":["Virological failure and resistance emergence during treatment with bictegravir\/emtricitabine\/tenofovir alafenamide or dolutegravir\/lamivudine in people living with HIV without prior resistance mutations: a real-world study"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2083-5992","authenticated-orcid":false,"given":"Thomas","family":"Drumel","sequence":"first","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, Service de Virologie , Nantes F-44000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Kimmerlin","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, Service de Virologie , Nantes F-44000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-1270","authenticated-orcid":false,"given":"Clotilde","family":"Allavena","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, Service de Maladies Infectieuses et Tropicales , Nantes F-44000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1133-5207","authenticated-orcid":false,"given":"Colin","family":"Deschanvres","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, Service de Maladies Infectieuses et Tropicales , Nantes F-44000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Billaud","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, Service de Maladies Infectieuses et Tropicales , Nantes F-44000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5657-842X","authenticated-orcid":false,"given":"Justine","family":"Sourice","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, Service de Virologie , Nantes F-44000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Andre-Garnier","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, Service de Virologie , Nantes F-44000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Raffi","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, INSERM, CIC 1413 , Nantes F-44000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"2026071509214553600_dkag247-B1","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1016\/S2352-3018(17)30016-4","article-title":"Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial","volume":"4","author":"Sax","year":"2017","journal-title":"Lancet HIV"},{"key":"2026071509214553600_dkag247-B2","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"2026071509214553600_dkag247-B3","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/QAI.0000000000002275","article-title":"Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials","volume":"83","author":"Cahn","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026071509214553600_dkag247-B4","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1007\/s12325-021-01883-8","article-title":"Real-world adherence to antiretroviral therapy among HIV-1 patients across the United States","volume":"38","author":"McComsey","year":"2021","journal-title":"Adv Ther"},{"key":"2026071509214553600_dkag247-B5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/jac\/dkae377","article-title":"Emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second-generation InSTIs in two- and three-drug regimens: the virostar-1 study","volume":"80","author":"Marcelin","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026071509214553600_dkag247-B6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/jac\/dkae392","article-title":"Comparing the long-term effectiveness and safety of dolutegravir\/lamivudine versus bictegravir\/emtricitabine\/tenofovir alafenamide fumarate as first-line regimens: a real life multicentre cohort","volume":"80","author":"Ciccullo","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026071509214553600_dkag247-B7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/hiv.70120","article-title":"Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025","volume":"27","author":"Ambrosioni","year":"2026","journal-title":"HIV Med"},{"key":"2026071509214553600_dkag247-B8","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1097\/QAD.0000000000004438","article-title":"Antiretroviral resistance in at least second-line HIV-1 treatment virologic failure with common InSTI-based regimens","volume":"40","author":"Marcelin","year":"2026","journal-title":"AIDS"},{"key":"2026071509214553600_dkag247-B9","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.3390\/v15091932","article-title":"Treatment emergent dolutegravir resistance mutations in individuals na\u00efve to HIV-1 integrase inhibitors: a rapid scoping review","volume":"15","author":"Tao","year":"2023","journal-title":"Viruses"},{"key":"2026071509214553600_dkag247-B10","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab297","article-title":"Case report: emergent resistance in a treatment-naive person with human immunodeficiency virus under bictegravir-based therapy","volume":"8","author":"Chamberlain","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2026071509214553600_dkag247-B11","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1016\/S2352-3018(21)00300-3","article-title":"A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial","volume":"9","author":"Landman","year":"2022","journal-title":"Lancet HIV"},{"key":"2026071509214553600_dkag247-B12","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/cid\/ciae006","article-title":"Two cases of viral re-suppression after M184V + R263K selection on dolutegravir\/lamivudine without treatment modification","volume":"79","author":"Ursenbach","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026071509214553600_dkag247-B13","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1128\/AAC.05181-14","article-title":"Combination of the R263K and M184I\/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity","volume":"59","author":"Singhroy","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071509214553600_dkag247-B14","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf087","article-title":"Three-year effectiveness of bictegravir\/emtricitabine\/tenofovir alafenamide as a switch strategy in the real world","volume":"12","author":"de Gea-Grela","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026071509214553600_dkag247-B15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/QAD.0000000000003070","article-title":"Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy-naive adults with HIV-1 infection","volume":"36","author":"Cahn","year":"2022","journal-title":"AIDS"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/8\/dkag247\/68882961\/dkag247.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/8\/dkag247\/68882961\/dkag247.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:21:55Z","timestamp":1784121715000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag247\/8734729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag247","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,2]]},"article-number":"dkag247"}}